Miller-Fisher syndrome after COVID-19: neurochemical markers as an early sign of nervous system involvement

Eur J Neurol. 2020 Nov;27(11):2378-2380. doi: 10.1111/ene.14473.

Abstract

Miller-Fisher syndrome (MFS) is classified as a variant of Guillain-Barré syndrome (GBS), accounting for 5%-25% of all GBS cases. Since the coronavirus disease-2019 (COVID-19) outbreak, increasing evidence has been reported of the neurological manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, affecting both the central and peripheral nervous system. Here we report the clinical course, detailed cerebrospinal fluid (CSF) profile including CSF/blood antibody status, and neurochemical characteristics of a patient with a typical clinical presentation of MFS after a positive SARS-CoV-2 infection test.

Keywords: COVID-19; Guillain-Barré syndrome; Miller-Fisher; SARS-CoV-2; coronavirus; neurofilament light chain; syndrome.

Publication types

  • Case Reports

MeSH terms

  • Biomarkers / cerebrospinal fluid
  • COVID-19 / cerebrospinal fluid
  • COVID-19 / complications*
  • COVID-19 / diagnosis
  • Humans
  • Male
  • Middle Aged
  • Miller Fisher Syndrome / etiology*
  • Nervous System Diseases / cerebrospinal fluid
  • Nervous System Diseases / diagnosis
  • Nervous System Diseases / etiology*
  • Neurofilament Proteins / cerebrospinal fluid
  • Treatment Outcome

Substances

  • Biomarkers
  • Neurofilament Proteins